Sponsor: AbbVie, Inc
Sponsor Study ID: M22-003
Study Title: Phase 3 Study of Epcoritamab, Rituximab, and Lenalidomide for First-Line Treatment of Follicular Lymphoma
CTO #: 103958
NCT Number: NCT06191744
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Non-Hodgkin's Lymphoma
Study Objectives: To assess the efficacy of ER2 compared to CIT in subjects with previously untreated FL. The hypothesis corresponding to the primary objective is that ER2 will improve the CR rate at Month 30 (CR30)/120 weeks when compared to standard of care CIT.